68Ga-labeled GRPR antagonist SB3 has demonstrated 88% sensitivity in identifying tumor lesions in biopsy-confirmed PCa patients who were therapy-naïve and scheduled for prostatectomy [69]. This evidence concerns the gene GRPR and posterior cortical atrophy.